Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe.
Vumerity is an oral drug designed to treat relapsing forms of MS, a chronic disease that affects the central nervous system.
Biogen already has four MS drugs on the market, but hopes to shift patients to Vumerity by emphasizing that it causes fewer gastrointestinal problems.
Biogen has not revealed how much Vumerity will cost, but its other MS drug, Tecfidera, had an annual net price of $79,500 at the end of 2018, according to an Institute for Clinical and Economic Review report cited by The Boston Globe.
Biogen holds the exclusive global license to market Vumerity and plans to bring it to the U.S. market soon.
Biogen will pay Alkermes $150 million as part of their collaboration agreement. In addition, Alkermes will also get a royalty on global sales.
Read the full article here.